Examining the overall global private investment activities of the anti-aging field provides insight to the commercial interest into this area. Performing a search of anti-aging within PitchBook 662 , an online source for investment data, reveals the overall venture capital activities. Anti-aging field refers to companies, which perform research and development of restorative treatments to prevent or treat the effects of aging and enhance lifespan. Research areas include genomic instability, telomere attrition, epigenetic alteration, loss of proteostasis, impaired nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication. The search revealed capital steadily raised within this industry (Figure ). 662 From 2012 through 2018, the total venture capital raised increased from $1.4B to over $12.2B. 2019 revealed the overall venture capital raised fell to just $7.0B. Capital raised continued to grow for 2019 to 2022 totaling over $30.6B in 2022 in total venture capital investment (Figure ). In the years 2013-2015 and 2020-2022 the investments were dominated by the United States, while in 2016-2019 investments from Asia were dominating. The venture capital investment data in this area clearly shows a recent and increasing commercial interest surrounding anti-aging agents, revealing its potential promise for therapeutic applications. In addition to the venture capital investments, in 2020 there was an investment of over $97B from the European Union, for the Horizon 2020 SME Instrument. The SME Instrument supports high-risk, and high-potential small and medium-sized initiatives to develop and provide new products, services and business models able to drive economic growth. This large investment enhanced significantly the Europe contribution in the total capital investments distribution (Figure ).